What You Can Learn From Frontage Holdings Corporation's (HKG:1521) P/E After Its 28% Share Price Crash
Feb 24
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Clinical Research and Equipment Industry Analysis
UpdatedMar 11, 2025
DataAggregated Company Financials
Companies9
- 7D6.5%
- 3M24.4%
- 1Y28.3%
- YTDn/a
In the last week, the Clinical Research and Equipment industry is up 5.9%, with WuXi Biologics (Cayman) up 5.8%. Meanwhile, Frontage Holdings actually underperformed within the industry, shrinking 15% in the last week. This takes the industry's 12 month performance to a gain of 32%. Earnings are forecast to grow by 42% annually.
Industry Valuation and Performance
Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 11 Mar 2025 | HK$198.7b | HK$35.8b | -HK$1,056,702,866.65 | 44.4x | -188.1x | 5.6x |
| Thu, 06 Feb 2025 | HK$165.5b | HK$35.8b | -HK$1,060,078,319.26 | 53.2x | -156.1x | 4.6x |
| Sat, 04 Jan 2025 | HK$152.1b | HK$35.7b | -HK$1,060,508,578.27 | 57.2x | -143.4x | 4.3x |
| Mon, 02 Dec 2024 | HK$136.7b | HK$35.9b | -HK$1,057,995,465.42 | 51.7x | -129.2x | 3.8x |
| Wed, 30 Oct 2024 | HK$162.2b | HK$35.6b | -HK$661,442,680.02 | 31.2x | -245.2x | 4.6x |
| Fri, 27 Sep 2024 | HK$151.5b | HK$36.1b | -HK$650,515,066.64 | 31.1x | -232.9x | 4.2x |
| Sun, 25 Aug 2024 | HK$93.8b | HK$36.0b | HK$2.0b | 15.8x | 46.6x | 2.6x |
| Tue, 23 Jul 2024 | HK$96.1b | HK$33.4b | HK$3.1b | 18.7x | 31.3x | 2.9x |
| Thu, 20 Jun 2024 | HK$92.8b | HK$33.4b | HK$3.1b | 22.8x | 30.1x | 2.8x |
| Sat, 18 May 2024 | HK$109.5b | HK$33.5b | HK$3.1b | 30.2x | 35.4x | 3.3x |
| Mon, 15 Apr 2024 | HK$111.9b | HK$33.6b | HK$3.1b | 32.2x | 36.1x | 3.3x |
| Wed, 13 Mar 2024 | HK$140.3b | HK$33.4b | HK$3.7b | 58.9x | 38.1x | 4.2x |
| Fri, 09 Feb 2024 | HK$125.9b | HK$32.6b | HK$3.0b | 46.4x | 41.7x | 3.9x |
| Sun, 07 Jan 2024 | HK$197.7b | HK$32.4b | HK$3.0b | 87.3x | 65.8x | 6.1x |
| Tue, 05 Dec 2023 | HK$225.1b | HK$32.5b | HK$3.0b | 81.5x | 74.8x | 6.9x |
| Thu, 02 Nov 2023 | HK$260.0b | HK$30.1b | HK$2.7b | 45.9x | 97.6x | 8.6x |
| Sat, 30 Sep 2023 | HK$245.6b | HK$30.2b | HK$2.7b | 43.6x | 91.8x | 8.1x |
| Mon, 28 Aug 2023 | HK$235.9b | HK$30.4b | HK$2.7b | 34.9x | 88x | 7.8x |
| Wed, 26 Jul 2023 | HK$227.4b | HK$28.6b | HK$2.8b | 25x | 82.5x | 8x |
| Fri, 23 Jun 2023 | HK$205.2b | HK$28.5b | HK$2.7b | 20.4x | 74.9x | 7.2x |
| Sun, 21 May 2023 | HK$228.3b | HK$29.0b | HK$2.8b | 22.2x | 80.4x | 7.9x |
| Tue, 18 Apr 2023 | HK$281.2b | HK$29.6b | HK$3.0b | 25.6x | 95.3x | 9.5x |
| Thu, 16 Mar 2023 | HK$266.1b | HK$26.4b | HK$2.1b | 23.7x | 128.3x | 10.1x |
| Sat, 11 Feb 2023 | HK$335.7b | HK$26.6b | HK$2.1b | 26.5x | 158.6x | 12.6x |
| Mon, 09 Jan 2023 | HK$343.6b | HK$26.4b | HK$2.1b | 28.1x | 164.8x | 13x |
| Wed, 07 Dec 2022 | HK$277.8b | HK$25.9b | HK$2.0b | 26.9x | 139.8x | 10.7x |
| Fri, 04 Nov 2022 | HK$223.5b | HK$25.3b | HK$1.8b | 21.8x | 124.1x | 8.8x |
| Sun, 02 Oct 2022 | HK$246.3b | HK$25.7b | HK$1.9b | 20.7x | 129.5x | 9.6x |
| Tue, 30 Aug 2022 | HK$366.7b | HK$25.4b | HK$2.8b | 10.8x | 131.6x | 14.4x |
| Thu, 28 Jul 2022 | HK$404.3b | HK$22.3b | HK$2.0b | 12.5x | 198.5x | 18.2x |
| Sat, 25 Jun 2022 | HK$400.0b | HK$22.4b | HK$2.1b | 16.4x | 192x | 17.8x |
| Mon, 23 May 2022 | HK$296.6b | HK$22.4b | HK$2.1b | 13.4x | 142.2x | 13.2x |
| Wed, 20 Apr 2022 | HK$311.7b | HK$23.3b | HK$2.3b | 14.8x | 133.7x | 13.4x |
| Fri, 18 Mar 2022 | HK$307.1b | HK$18.7b | HK$2.8b | 19.9x | 108.9x | 16.4x |
Price to Earnings Ratio
108.9x
Current Industry PE
- Investors are pessimistic on the Hong Kong Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 8.1x is higher than the industry's current PS ratio of 5.6x.
Past Earnings Growth
- Total earnings for the Life Sciences Tools and Services industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 24% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Hong Kong Clinical Research and Equipment compare with similar industries?
| HK Market | 3.28% | |
| Healthcare | 2.58% | |
| Life Sciences | 6.51% | |
| Clinical Research and Equipment | 6.51% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$23.75 | 6.0% +HK$5.5b | 34.2% | PE34.6x | |
| 2268 WuXi XDC Cayman | HK$34.65 | 8.5% +HK$3.2b | 71.5% | PE65.3x | |
| 1548 Genscript Biotech | HK$13.54 | 7.6% +HK$2.1b | -12.8% | PS3.7x | |
| 2228 XtalPi Holdings | HK$6.68 | 6.5% +HK$1.4b | n/a | PS107.9x | |
| 1873 Viva Biotech Holdings | HK$1.37 | 3.8% +HK$105.6m | 163.5% | PS1.4x |